The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc. and German partner BioNTech SE’s Covid-19 vaccine for adolescents aged between 12 and 15 years by early next week, the New York Times reported on May 3, citing federal officials familiar with the regulatory agency’s plans.

The U.S. government will allot nearly 85 percent less Johnson & Johnson Covid-19 vaccines to states next week, data from Centers for Disease Control and Prevention (CDC) showed.

Emergent BioSolutions’ Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19 showed that the addition of the treatment to Gilead Sciences’ remdesivir did not provide clinical benefit compared to standard of care plus placebo in hospitalized adult COVID-19 patients with symptoms for less than 12 days.

Johnson & Johnson said on March 31 the company had found a problem with a batch of the drug substance for its Covid-19 vaccine being produced by Emergent BioSolutions, and said the batch did not advance to the final fill-and-finish stage.

Dr. Anthony Fauci, the top U.S. infectious disease expert, said on March 14 he hopes former President Donald Trump will push his supporters to get the Covid-19 vaccine and emphasized that pandemic-related restrictions should not be lifted prematurely.

FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps: NYT (Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday. The FDA is expected to […]

Johnson & Johnson is on track to roll out a single-shot coronavirus vaccine in March, and plans to have clear data on how effective it is by the end of January or early February, the U.S. healthcare company’s chief science officer said.

Scientists at the National Institutes of Health and Moderna Inc. may take about two months to determine whether doses of the company’s Covid-19 vaccine can be halved to double the supply of the shots in the U.S., according to the agency.

The United Kingdom, which was the first to grant authorization to the vaccine developed by Pfizer and Moderna, is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.

Ugur Sahin, founder and chief executive officer of Germany-based BioNTech, sees the potent efficacy of BNT162b2 – the vaccine developed by his company and partner Pfizer – as the possible “beginning of the end” of the coronavirus pandemic.